Figure 2From: TLE3 as a candidate biomarker of response to taxane therapyKaplan-Meier plots in the Clearview Cancer Institute in Huntsville 'discovery' cohort. Patients in this cohort were treated with (a) any adjuvant chemotherapy regimen, (b) no adjuvant chemotherapy, (c) CMF, (d) AC (± F) ± taxane, (e) AC (± F) but not a taxane. AC, doxorubicin + cyclophosphamide; CMF, cyclophosphamide, methotrexate, and 5-fluorouracil; F, 5-fluorouracil.Back to article page